Teva Pharmaceutical Industries (NYSE:TEVA) has been rising and falling as per the market's reactions to series of events. Over the past three years, holders
gained, while recent buyers are not as fortunate. The stock has seen various investment firms like
Janney Montgomery Scott LLC and
GAMMA Investing LLC buying sizable shares leading to a
14% rise in the stock price. Meanwhile, large scale selloff from top executives has also happened.
Regulatory factors triggered the selloff and some analysts suggest with its low price, it is the
best pharmaceutical stock to invest in right now. Overcoming sales miss, large investments, upgrades and
strong-buy ratings from analysts have played roles in its performance. Recent
Senior notes offering of $2 billion and
cost savings plans of $700M by 2027 received maximum attention. Analysts’ views range across, with a few suggesting the stock is ready to
surge despite market worries and challenges. Finally, the latest
coverage initiation by Goldman Sachs and Truist Financial has been positively received.
Teva Pharmaceutical Stocks News Analytics from Wed, 06 Nov 2024 08:00:00 GMT to Fri, 20 Jun 2025 11:56:29 GMT -
Rating 3
- Innovation 2
- Information 6
- Rumor -3
